Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X: a case report and literature review

Bi, Huanhuan and Ren, Dunqiang and Wu, Jieqiong and Ding, Xiaoqian and Guo, Caihong and Miura, Satoru and Megyesfalvi, Zsolt and Arulananda, Surein and Wang, Hongmei (2021) Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X: a case report and literature review. ANNALS OF TRANSLATIONAL MEDICINE, 9 (24). No.-1805. ISSN 2305-5839

Preview

Text 86840-PB3-3179-R2.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (3MB) | Preview

Abstract

Asians who develop non-small cell lung cancer (NSCLC) have a chance of approximately 50% of harboring the epidermal growth factor receptor (EGFR) mutation. The G719X mutation in EGFR has 3 subtypes (i.e., G719A, G719C, or G719S), all of them being classified as uncommon EGFR mutations. The EGFR mutation G719X is most often associated with lung adenocarcinoma. Conversely, its occurrence in lung squamous cell carcinoma is rare. Its response to tyrosine kinase inhibitor (TKI) treatment remains unknown. A 50-year-old Asian male with no smoking history was admitted to our hospital (Affiliated Hospital of Qingdao University) with an irritating dry cough and 1 month of progressive dyspnea. The patient was diagnosed with lung squamous cell carcinoma (cT4N3M0, stage IIIC). Lung biopsy revealed the presence of EFGR G719X mutation. The patient received a tracheobronchial stent, targeted therapy, chemotherapy, seed implantation and radiotherapy, and survived for 25.4 months following diagnosis. It is crucial that gene mutation analysis is performed in non-smoking male squamous cell carcinoma patients. Compared to lung adenocarcinoma patients with rare G719X mutation, this lung squamous cell carcinoma patient with G719X-mutant tumor had a higher sensitivity to 2nd-generation EGFR-TKI treatment, but similar progression-free survival. Importantly, the patient clearly benefited from the used comprehensive treatment plan. This article seeks to shed light on the treatment of lung squamous cell carcinoma patients with the uncommon EGFR G719X mutation.

Actions (login required)

Edit Item